Trial |
Aspirin |
Control |
Odds Ratio |
Duration of Therapy |
Annual Approximate Control Group Risk |
Approximate Excess Bleeding Events per 1,000 Patients Treated per Year |
---|---|---|---|---|---|---|
BMD5 |
13/3,429 |
6/1,710 |
1.08 |
5.8 years |
0.06% |
0.05 |
PHS4 |
23/11,037 |
12/11,034 |
1.92 |
5 years |
0.02% |
0.2 |
TPT7 |
3/1,268 |
2/1,272 |
1.51 |
6.8 years |
0.02% |
0.12 |
HOT8 |
14/9,399 |
15/9,391 |
0.93 |
3.8 years |
0.04% |
0.03 fewer events |
PPP9 |
2/2,226 |
3/2,269 |
0.67 |
3.6 years |
0.04% |
0.12 fewer events |
*BMD indicates British Male Doctors' Trial; HOT, Hypertension Optimal Treatment Trial; NR, not reported; PHS, Physicians' Health Study; PPP, Primary Prevention Project; TPT, Thrombosis Prevention Trial.